Metformin vs Mounjaro: what the evidence actually shows

The biggest misconception: metformin is not a weight-loss medicine

A common belief on forums and in comment sections is that metformin and Mounjaro are broadly equivalent alternatives for people who want to lose weight. That is not accurate. Metformin (biguanide) is licensed in the UK for type 2 diabetes, where it reduces glucose production in the liver and improves insulin sensitivity. Weight changes seen in some people who take it are a secondary effect, not the treatment goal, and the clinical evidence for meaningful weight loss in people without diabetes is modest at best. It has no UK licence for weight management. Mounjaro, by contrast, was specifically developed and licensed for weight management alongside a reduced-calorie diet and increased activity, as well as for type 2 diabetes.

This distinction matters because the evidence base and the regulatory oversight look completely different. Prescribing metformin for weight loss in someone without diabetes is an off-label decision a GP can make, but it falls outside the product's intended indication. Mounjaro's weight-management indication is fully licensed by the MHRA, supported by substantial phase-3 trial data and recommended by NICE in their appraisal TA1026.

Correcting that misconception is where this comparison has to start, because it changes the question entirely. If you want a thorough side-by-side breakdown before speaking to a prescriber, our metformin versus Mounjaro guide walks through the evidence in detail and may help you frame the right questions.

How the two medicines work and what the trial data shows

Metformin's primary action is hepatic: it suppresses glucose output from the liver and sensitises peripheral tissue to insulin. Appetite effects, where they exist, appear to be secondary to improved insulin signalling and possibly some gut-hormone modulation. Trial data suggest that in people with type 2 diabetes, metformin produces modest average weight changes of around 1–3 kg over 12–24 weeks. In people without diabetes the picture is less clear, and robust randomised controlled data for weight management as a primary outcome are limited.

Mounjaro activates both the GLP-1 and GIP receptors simultaneously — a dual mechanism that no other licensed UK weight-loss medicine uses. This slows gastric emptying, reduces appetite signals and alters the reward response to food. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, adults without diabetes taking tirzepatide 15mg achieved around 20–21% average body-weight reduction over 72 weeks alongside lifestyle changes. In the SURMOUNT-5 head-to-head trial (NEJM, 2025), tirzepatide produced greater average weight reduction than semaglutide 2.4mg, which itself produced approximately 15% average reduction in its phase-3 programme.

The gap between those figures and what metformin produces in weight management studies is substantial. That said, for people with type 2 diabetes, metformin remains a well-established, inexpensive and broadly safe first-line treatment for glucose control, and many people take both medicines under their prescriber's guidance. Comparing them for weight loss is a narrower question.

Side-effect profiles and practical differences

The two medicines share some gastrointestinal overlap but diverge in character. Metformin's most common side effects are GI: loose stools, nausea, stomach discomfort, particularly in the early weeks or with higher doses. Extended-release formulations reduce this for many people. Long-term use can affect B12 absorption, so periodic monitoring is standard. It is generally not associated with low blood sugar in people without diabetes, which is one reason it remains a first-line diabetes choice.

Mounjaro's side-effect profile is also GI-led: nausea, diarrhoea, constipation and reflux are the most commonly reported effects, typically most noticeable after starting or after a dose step, and often settling over a couple of weeks. The treatment starts at 2.5mg as a tolerability step, not a therapeutic one, and is titrated by a prescriber at roughly four-week intervals. The MHRA carries an enhanced monitoring designation (Black Triangle, ▼) for tirzepatide. The NHS tirzepatide information page lists the full side-effect profile and the signs that warrant prompt medical attention.

One practical difference that patients often find significant: metformin is an oral tablet taken daily; Mounjaro is a once-weekly injection via a pre-filled KwikPen. For people who travel regularly, work shift patterns or are trying to build a routine around something like Monday orders or school-holiday schedules, the weekly rhythm can actually feel simpler. Staying well hydrated during titration is also worth planning for, and our guide to the best electrolytes to use alongside Mounjaro covers what to look for and what to avoid.

Eligibility, NHS access and private routes

Metformin on the NHS is routine: a GP can prescribe it for type 2 diabetes at any point, and it is inexpensive. Off-label weight-management use is at the prescriber's discretion.

Mounjaro on the NHS follows the phased NICE rollout. Currently, people with a BMI of 40 or above and four or more of the five qualifying conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes) may be eligible, with criteria broadening to BMI 35–39.9 plus four conditions from around June 2026. GP practices can prescribe under the 2026/27 contract, though participation varies. Ethnic-background thresholds are 2.5 kg/m² lower under NICE guidance. Many people who are clinically suitable do not yet meet the NHS criteria or would prefer not to wait. A private prescription route through a regulated online pharmacy is the alternative, subject to a full clinical assessment. If you want to understand the cost landscape before consulting, our Mounjaro pricing guide sets out what a legitimate private prescription typically includes.

Any comparison between these two medicines as weight-loss options needs to account for whether Mounjaro is even the right question for you. Our free consultation is the starting point: a GPhC-registered prescriber reviews your full picture and tells you what is clinically appropriate, with no obligation.

Which option suits you is not a decision this page can make. It is a clinical decision made with your prescriber, based on your diagnosis, BMI, existing conditions and treatment history. You can explore the broader weight-loss treatment options available, or read about how tirzepatide compares to other agents, including our Feel Pro Metabolic versus Mounjaro comparison, on our tirzepatide comparison page. Our clinical team profile is at our prescribers page if you want to know more about who reviews your consultation.